You're sitting across from a financial advisor who describes an investment as a sensible way to generate income without taking the full risk of the stock market. The brochure highlights a generous coupon, a defined maturity date, and words such as “principal protection” or “downside buffer.” You ask whether your retirement savings can be lost. The answer comes in careful language, buried in a prospectus you're expected to understand.

Later, the underlying stock falls, the coupon stops, or you discover that selling requires accepting a steep discount. The product you thought was a conservative income investment turns out to be a complex claim against a bank, tied to conditions you never fully understood. For many investors, the central problem isn't that structured products exist. It's that brokers recommend them without explaining what the investor must surrender to receive the advertised yield.

The Allure and Reality of Structured Notes

A structured note combines a traditional security, such as a bond, with a derivative component. The U.S. Securities and Exchange Commission describes structured notes as instruments that join those two elements, while also noting that they don't receive the Investment Company Act protections that apply to mutual funds and exchange-traded funds. The SEC's explanation of structured notes makes the legal and practical point clear: this isn't the same ownership interest as a diversified fund.

The derivative changes the note's payoff. Instead of receiving a return that rises and falls in a relatively direct relationship with an asset, you may receive a coupon only if specified conditions remain intact. A barrier may change the repayment terms. A cap may limit your gain. A basket of securities may determine the result, even though you never directly own that basket.

Practical rule: If you can't explain exactly what happens after a barrier is breached, you don't understand the investment well enough to buy it.

The appeal is easy to understand. A retiree wants income. A broker presents a note linked to an index, stock, interest rate, or basket of assets. The investor hears “enhanced yield” and “some protection.” The issuer, however, has engineered a contract with nonlinear outcomes. A modest movement in the underlying can produce a disproportionately different result for the noteholder.

A large market with ordinary investors in it

Structured products for retail investors are not a niche instrument. European households held more than EUR 392 billion in structured retail products in 2024, an increase of 8% from 2023, according to ESMA's market report on retail investment products. Earlier European estimates identified more than EUR 2 trillion in highly complex retail structured products sold to households since the late 1990s. In the United States, annual sales increased from approximately $50 billion per year before 2020 to around $115 billion in 2023, with monthly sales reaching USD 13.7 billion in August 2023, according to the same report.

Those figures show distribution and demand, not safety. Products can become widely sold while remaining difficult for ordinary investors to evaluate. Regulators have treated them as complex, higher-risk instruments precisely because a polished income pitch can conceal issuer risk, derivative exposure, limited liquidity, and a payoff that depends on several conditions at once.

The investor's real question shouldn't be, “What coupon does this note pay?” It should be, “What risks am I accepting, what upside am I giving away, and what happens if I need my money before maturity?”

Common Types of Structured Products Explained

A broker can present a structured note as a conservative income solution while the documents reveal a concentrated bet on one stock, index, or basket. The product name rarely tells the whole story. The controlling terms appear in the prospectus, pricing supplement, and payoff diagram. Common products sold to individual investors include principal-protected notes, reverse convertibles, equity-linked or enhanced-participation notes, autocallables, and other hybrid notes, as described in the SEC investor bulletin on structured notes.

A principal-protected note is not a government guarantee, and it does not promise that the account value cannot fall before maturity. Protection depends on the issuing bank's creditworthiness and on the precise conditions in the note. Many products also limit upside through a participation rate or maximum payment. Read the SEC guidance before treating the word “protected” as a complete description of the investment.

The broker should identify the issuer, underlying asset, maturity, barrier, cap, participation rate, observation dates, and exact loss formula in writing. If those terms are difficult to explain, the product is difficult to evaluate and may be unsuitable for a retail account.

A reverse convertible generally pays a coupon in exchange for exposure to an underlying asset. If that asset performs poorly and the terms permit repayment in shares or a cash amount based on the declined asset, the investor can suffer a substantial loss after receiving only the advertised income. The coupon does not remove the downside. It compensates the investor for accepting it.

The trigger controls the result

Autocallables require particular scrutiny. The note may redeem automatically when the underlying reaches a specified level on an observation date. That feature can end the income stream when the coupon looks attractive, leaving the investor to reinvest under changed market conditions. A broker who emphasizes the yield but fails to explain the call trigger, concentration, or loss conditions has not presented the product fairly.

Equity-linked notes can include a barrier that changes the repayment formula. A participation rate may give the investor only part of an increase in the underlying, while a cap can stop further gains. A memory coupon may allow missed payments to accumulate only if later conditions are satisfied. These terms determine whether the product delivers income, limited equity exposure, or an amplified loss position.

For a practical review, compare structured product examples with the actual documents for your investment. Do not rely on the product name or sales presentation. If the broker concealed the mechanics or recommended excessive concentration, those facts may support a FINRA arbitration claim.

Liquidity Traps and Pricing Opacity

The sales presentation usually focuses on what happens at maturity. Your financial life doesn't. You may need funds for medical care, a family emergency, taxes, or ordinary living expenses before the note matures. That's when many investors discover that the apparent stability of a structured product depended on holding an issuer-created contract until the end.

Secondary markets can be thin or nonexistent. A bank may provide an indication of value, but that doesn't guarantee an active market or a fair exit price. If you sell early, the price can reflect market volatility, the issuer's credit spread, remaining time, hedging costs, and the bank's discretion. A note showing an attractive maturity value can still produce a painful loss when liquidated before that date.

The price isn't as transparent as the coupon

The derivative component makes the note harder to price than a conventional bond. The embedded options may have values that change as volatility, interest rates, time, and the underlying asset move. The investor sees one combined security, while the issuer has calculated a package of components and embedded its own economics in the offering price.

Regulatory materials identify opaque and expensive fee structures, limited secondary-market activity, and pricing difficulty as recurring concerns. The SEC study on structured securities also explains that principal protection can fail if the issuer defaults or if the product's protection conditions aren't satisfied. The advertised coupon therefore isn't free income. It may compensate you for surrendering liquidity, accepting issuer credit risk, giving up upside, or taking a loss that appears only after a barrier event.

A broker who says, “You can always sell if you need the money,” should be asked a different question: “At what price, under what formula, and who is obligated to buy it?” If the answer is unclear, accessibility is being assumed rather than established.

The important distinction: A stated maturity value is not the same as a guaranteed exit value.

Your records may show a valuation supplied by the issuer rather than a price created by competitive trading. That difference matters when an advisor describes the investment as liquid or cash-like. It also matters in a recovery claim, because the offering documents, account statements, valuation history, and communications can reveal whether the broker understood the limitations and explained them accurately.

For a focused discussion of the downside features investors should examine, review structured product risks. A high coupon doesn't make an illiquid position suitable for money you may need.

Suitability Failures and Disclosure Gaps

A retiree may be shown a structured note with an attractive coupon and told it can provide dependable income. That description is incomplete if the note can lose principal, restrict access to funds, depend on a market path, or expose the customer to the issuing bank. A broker must assess whether those risks fit the customer's objectives, investment experience, liquidity needs, age, financial condition, and tolerance for loss. The analysis matters most when the account supports regular living expenses.

Lengthy paperwork does not establish meaningful disclosure. Legalistic language may describe a barrier, knock-in event, issuer obligation, or capped participation without answering the question the customer needs answered: “How much can I lose, and when?” A headline yield can conceal concentration in one issuer, one underlying asset, or one loss formula.

What regulators expect from firms

FINRA guidance emphasizes that firms recommending complex products must conduct reasonable diligence to understand their risks and rewards before recommending them. The FINRA guidance discussed by the SEC makes clear that handing over a prospectus does not complete that obligation. The firm must understand how the product works and have a reasonable basis for believing the recommendation suits the customer.

That duty also requires practical review of the proposed sale. The broker should understand the barrier, maturity terms, issuer exposure, early-sale pricing, and circumstances that can reduce or eliminate principal. If the firm cannot explain those features in plain language, it should not recommend the product to a customer who cannot independently evaluate them.

In the European Union, the PRIIPs framework covers structured products marketed to retail investors when repayment fluctuates with reference values or assets the investor does not directly purchase. Before making such a product available, the manufacturer must prepare and publish a Key Information Document. The PRIIPs regulation requires that document before retail distribution.

EU authorities describe these investments as products linked to reference indices, prices, or rates. The consumer-facing KID must explain the main features, potential gains, risks, and costs before a proposal or contract. That requirement has applied since 1 January 2018, according to the European insurance and pensions authority's PRIIPs overview.

Disclosure doesn't cure an unsuitable recommendation

A disclosure may support a broker's defense, but it does not turn an unsuitable sale into a suitable one. A conservative investor needing dependable liquidity may not be an appropriate buyer for a note with issuer risk, capped gains, path-dependent returns, and a severe discount on early sale.

The UK FCA identified product governance and distribution controls as regulatory concerns in its review of structured products. The FCA review of structured-product governance supports a direct conclusion: firms have responsibilities before and during the sale, not only after a complaint.

If an advisor called a complex note a bond substitute, cash alternative, or safe retirement-income product without explaining the loss scenarios, preserve emails, messages, account statements, and meeting notes. In a FINRA arbitration claim, the difference between providing a document and ensuring meaningful understanding can determine whether the broker met its duties.

How Concentration and Complexity Destroy Portfolios

A structured note can look manageable in isolation. The portfolio may become dangerous when an advisor fills it with notes tied to similar underlyings, issued by the same bank, or exposed to the same market conditions. The investor may believe there is diversification because the account contains several product names. In reality, those positions can share one issuer, one sector, one barrier risk, or one adverse market scenario.

“Worst-of” can turn several assets into one weak link

A worst-of note calculates performance using the weakest underlying in a group. That structure can make a portfolio appear tied to multiple companies while exposing the investor to the single asset that performs worst. If the weakest asset crosses a barrier, the investor may face the loss formula attached to that asset, even if the other underlyings performed well.

The danger grows when the notes also include autocall triggers, barrier levels, memory coupons, and volatility overlays. Each feature creates another condition to monitor. A customer may own multiple notes with different observation dates and formulas without being able to determine the account's combined exposure under a stressed market.

FINRA's 2026 review identified higher-risk worst-of structured notes, lack of principal protection, and customer concentration as recurring supervisory concerns. It also noted that some investors suffered significant portfolio losses from these products. The discussion of structured-note supervision and infrastructure highlights why complexity and monitoring deserve attention at the portfolio level, not merely in the individual trade ticket.

Portfolio test: Count the issuer, underlying sectors, barriers, maturity dates, and loss formulas. Do not count only the number of line items.

A broker who recommends multiple notes from one issuer may create concentrated credit exposure even when the underlying assets differ. A broker who places retirement savings into several notes linked to volatile equities may create market concentration even when each note carries a different title. A broker who fails to explain the combined effect may have failed to supervise the account appropriately.

The right question isn't whether any single note seemed reasonable. It's whether the recommendations, viewed together, exposed the customer to a level of loss that the customer couldn't absorb or understand. That assessment should include income needs, emergency liquidity, existing securities, issuer exposure, and the practical ability to monitor every trigger until maturity.

Legal Remedies for Investment Losses

Investors are not automatically liable for a structured-product loss just because they signed a disclosure. The legal issue often concerns the conduct surrounding the recommendation. A brokerage firm or advisor may face claims when the product was unsuitable, the risks were misrepresented, the firm failed to supervise the recommendation, or the advisor lacked a reasonable basis for selling the product.

FINRA arbitration commonly addresses disputes involving brokerage firms and registered representatives. Potential theories can include unsuitability, breach of fiduciary duty, negligent misrepresentation, failure to supervise, and inadequate due diligence. The precise claims depend on the account relationship, documents, communications, governing agreements, and applicable law.

The issuing bank isn't always the only target

Many investors assume they must sue the bank that issued the note. That isn't necessarily correct. If your broker recommended the product, the brokerage firm may be responsible for the recommendation, customer-specific suitability analysis, supervision, and representations made during the sale.

That distinction matters because the claim may focus on why the product entered your account, not only on how the underlying asset performed. A market loss alone doesn't establish misconduct. A loss following a recommendation to place retirement funds into an opaque, illiquid, concentrated note may present a different analysis, particularly when the advisor promised safety or dependable income.

FINRA's 2012 guidance emphasized that firms must conduct reasonable diligence before recommending complex products, including structured notes, to understand their risks and rewards. The structured-note investment dispute overview provides a starting point for understanding how these disputes may be evaluated.

What the process usually requires

A securities attorney will typically examine:

1. The recommendation: What did the advisor say about safety, income, liquidity, and downside?
2. The customer profile: Was the investor retired, dependent on income, risk-averse, or in need of accessible funds?
3. The product documents: What did the prospectus, pricing supplement, KID, and risk disclosures say?
4. The account concentration: How much exposure existed to the issuer, underlying assets, sectors, and related notes?
5. The loss history: Did the investor hold to maturity, sell at a discount, receive partial repayment, or lose principal after a trigger event?

Securities cases are often handled through contingency-fee arrangements, meaning the attorney's fee is generally tied to recovery rather than requiring the investor to pay hourly fees throughout the case. The agreement should explain fees, expenses, arbitration costs, and the circumstances in which the client may owe expenses regardless of outcome. A consultation can also clarify whether a claim belongs in FINRA arbitration, court, or another forum.

Evaluating Your Claim and Next Steps

Act before documents disappear and memories become less precise. A structured-product claim depends on the details of the sale, and those details may exist in emails, account notes, recorded calls, confirmations, and marketing materials that you don't initially realize are important.

Gather the following:

• Account statements: Preserve statements showing purchases, valuations, coupon payments, redemptions, and losses.
• Trade confirmations: Keep the confirmation for every note, including the issuer, CUSIP, purchase date, amount, and price.
• Offering documents: Save the prospectus, pricing supplement, term sheet, KID, and any risk summary.
• Sales communications: Collect emails, text messages, brochures, presentations, and handwritten notes from meetings.
• Financial profile records: Identify your stated objectives, liquidity needs, risk tolerance, age, income needs, and existing investments.
• Loss evidence: Record early-sale prices, missed coupons, barrier events, maturity payments, and conversations about the decline.

Don't alter or annotate original documents. Make copies and write a separate timeline while events remain fresh. Include what the advisor promised, what you understood, when you learned about the loss, and whether you asked to sell or raise concerns.

Timing can affect your options

Arbitration eligibility rules, contractual provisions, and statutes of limitations can restrict a claim if you wait. The applicable deadline depends on the facts and jurisdiction, so an investor shouldn't assume that holding the note or waiting for maturity preserves every legal right.

A securities attorney can evaluate the product structure and the recommendation together. That review may identify whether the case involves a single unsuitable note, a broader failure to diversify, concentration across related products, misleading safety representations, or inadequate supervision. The FINRA arbitration process explains the general forum investors may use when pursuing claims against brokerage firms and associated persons.

If you would like a free consultation to discuss the investment loss recovery process in more detail, call Kons Law Firm at (860) 920-5181 for a FREE, NO OBLIGATION consultation. Don't wait for a confusing statement or an issuer response to determine your next move. The sooner counsel reviews the documents, the sooner you can understand whether recovery may be available.

Kons Law represents investors in disputes involving structured products and other investment losses through FINRA arbitration and court actions, with consultations available to discuss the facts of your case. Visit Kons Law to submit your information and speak with a securities attorney about your potential claim.